Floatz logo

Rfviii

Hemophilia A

BayerPhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the Hemophilia A cohort.

Asset / SponsorPhaseRating
Rurioctocog Alfa Pegol
Takeda
Phase 4BBB
bay94-9027
Bayer
Phase 4BBB
Emicizumab
Emory University
Phase 4BBB
Fitusiran
Sanofi
Phase 4BBB
Xyntha
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB

View all 50 →

Same molecule, other indications

Rfviii is also rated in:

Blood Coagulation DisordersDormant
BBB
Indicative ·
75 / 100
View asset →
Severe Hemophilia ADormant
BBB
Indicative ·
74 / 100
View asset →
hemophiliaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →